← All trials
NCT03386149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 28, 2017
- Primary completion
- Aug 31, 2018
- Completion date
- Sep 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 74
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kyung Hee UniversityLead sponsor
- Kyung Hee UniversityCollaborator
- Kyung Hee UniversityReponsible party - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Dongguk UniversityCollaborator
- Daegu Haany UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.